|
|
|
Volumn 26, Issue 1 SUPPL. 2, 1999, Pages 109-111
|
|
Paclitaxel in the treatment of hormone-refractory prostate cancer
a
a
a
7308 CCGC
*
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANDROGEN;
ESTRAMUSTINE;
ETOPOSIDE;
PACLITAXEL;
PROSTATE SPECIFIC ANTIGEN;
ANTINEOPLASTIC ACTIVITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER HORMONE THERAPY;
CANCER MORTALITY;
CANCER PALLIATIVE THERAPY;
CLINICAL TRIAL;
CONFERENCE PAPER;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MALE;
NEUTROPENIA;
ORAL DRUG ADMINISTRATION;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
ESTRAMUSTINE;
ETOPOSIDE;
HUMANS;
MALE;
NEOPLASMS, HORMONE-DEPENDENT;
PACLITAXEL;
PROSTATIC NEOPLASMS;
|
|
EID: 0033062292
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (31)
|
|
References (20)
|
